Methods of treating or preventing respiratory conditions
View Patent ↗The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.
1. A method of treating a respiratory condition in a human subject, the method comprising administering to the human subject a population of human cells enriched for STRO-1 bright mesenchymal precursor cells or progeny thereof.
2. The method of claim 1 , wherein the respiratory condition is an acute respiratory condition or a chronic respiratory condition.
3. The method of claim 1 , wherein the respiratory condition is an inflammatory respiratory condition, an obstructive respiratory condition or a restrictive respiratory condition.
4. The method of claim 3 , wherein the respiratory condition is an obstructive respiratory condition or an inflammatory lung condition.
5. The method of claim 4 , wherein the respiratory condition is asthma.
6. The method of claim 5 , wherein the asthma is acute asthma, chronic asthma, severe asthma and/or refractory asthma.
7. The method of claim 6 , wherein the asthma is long acting beta agonist (LABA) refractory asthma or steroid refractory asthma.
8. The method of claim 5 , wherein the asthma is acute asthma.
9. The method of claim 5 , wherein the asthma is refractory asthma.
10. The method of claim 3 , wherein the respiratory condition is a restrictive respiratory condition.
11. The method of claim 10 , wherein the respiratory condition is idiopathic pulmonary fibrosis.
12. The method of claim 1 , wherein the condition is allergy to house dust mite allergen (HDM) and the allergen is HDM.
13. The method of claim 1 , wherein the population enriched for STRO-1 bright mesenchymal precursor cells or progeny thereof is administered systemically.
14. The method of claim 13 , wherein the population enriched for STRO-1 bright mesenchymal precursor cells or progeny thereof is administered intravenously or intranasally.
15. The method of claim 1 , wherein the population enriched for STRO-1 bright mesenchymal precursor cells or progeny thereof is administered a plurality of times.
16. The method of claim 1 , comprising administering a further dose of the population when one or more of the following occurs:
(i) a subject begins to persistently wheeze and/or cough and/or have chest tightness and/or have difficulty breathing;
(ii) a subject shows one or more of the following when assessed by spirometer:
a) 20% difference on at least three days in a week for at least two weeks;
b)≥20% improvement of peak flow following treatment with: 10 minutes of inhaled β-agonist; six weeks of inhaled corticosteroid; 14 days of 30 mg prednisolone;
c) ≥20% decrease in peak flow following exposure to a trigger;
(iii) bronchoscopy showing abnormal cells and/or foreign substances and/or blockages in the respiratory tract of a subject; or
(iv) chest CT scan showing abnormalities of the blood vessels in the lungs, accumulation of blood or fluid in the lungs, bronchiectasis, pleural effusion or pneumonia.
17. The method of claim 1 , comprising administering a dose of the population sufficient to achieve one or more of the following:
(i) improved bronchial hyperresponsiveness;
(ii) reduced eosinophil infiltration of the lung or bronchoalveolar lavage fluid;
(iii) reduced neutrophil infiltration of the lung or bronchoalveolar lavage fluid;
(iv) reduced late asthmatic response;
(v) reduced early asthmatic response; and/or
(vi) reduced lung remodeling/fibrosis.
18. The method of claim 1 , comprising administering between 1×10 6 to 150×10 6 STRO-1 bright mesenchymal precursor cells or progeny thereof.
19. The method of claim 1 , comprising administering a whole body dose of STRO-1 bright mesenchymal precursor cells or progeny thereof.
20. The method of claim 19 , comprising administering 150×10 6 STRO-1 bright mesenchymal precursor cells or progeny thereof in 10 mL to the human subject.
21. The method of claim 1 , wherein the population enriched for STRO-1 bright mesenchymal precursor cells or progeny cells is allogeneic.
22. The method of claim 1 , wherein the respiratory condition is an IgE-mediated respiratory allergic response to an allergen that causes a respiratory condition in humans.